Lyfgenia

Overview

lovotibeglogene autotemcel

gene therapy

• gene therapy
• myelosuppressive effects

Avoid/Use Alternative

• abacavir
Lyfgenia (lovotibeglogene autotemcel)

+

abacavir

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + abacavir

avoid combo; D/C abacavir at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• atazanavir
Lyfgenia (lovotibeglogene autotemcel)

+

atazanavir

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + atazanavir

avoid combo; D/C atazanavir at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• bictegravir
Lyfgenia (lovotibeglogene autotemcel)

+

bictegravir

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + bictegravir

avoid combo; D/C bictegravir at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• cabotegravir
Lyfgenia (lovotibeglogene autotemcel)

+

cabotegravir

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + cabotegravir

avoid combo; D/C cabotegravir at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• chloramphenicol
Lyfgenia (lovotibeglogene autotemcel)

+

chloramphenicol

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + chloramphenicol

use alternative or monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• cladribine oral
Lyfgenia (lovotibeglogene autotemcel)

+

cladribine oral

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + cladribine oral

use alternative or monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• cobicistat
Lyfgenia (lovotibeglogene autotemcel)

+

cobicistat

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + cobicistat

avoid combo; D/C cobicistat at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• crizanlizumab
Lyfgenia (lovotibeglogene autotemcel)

+

crizanlizumab

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + crizanlizumab

avoid combo; D/C crizanlizumab at least 2mo prior to mobilization and until all apheresis cycles completed; D/C crizanlizumab at least 2mo prior to myeloablative conditioning: combo may interfere w/ mobilization or conditioning agents (mechanism unknown)

• darunavir
Lyfgenia (lovotibeglogene autotemcel)

+

darunavir

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + darunavir

avoid combo; D/C darunavir at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• deferasirox
Lyfgenia (lovotibeglogene autotemcel)

+

deferasirox

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + deferasirox

D/C deferasirox at least 7 days prior to mobilization or conditioning initiation; avoid combo at least 6mo after lovotibeglogene autotemcel infusion: combo may incr. risk of myelosuppression, bleeding (additive effects)

• deferiprone
Lyfgenia (lovotibeglogene autotemcel)

+

deferiprone

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + deferiprone

D/C deferiprone at least 7 days prior to mobilization or conditioning initiation; avoid combo at least 6mo after lovotibeglogene autotemcel infusion: combo may incr. risk of myelosuppression, bleeding (additive effects)

• deferoxamine
Lyfgenia (lovotibeglogene autotemcel)

+

deferoxamine

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + deferoxamine

D/C deferoxamine at least 7 days prior to mobilization or conditioning initiation; avoid combo at least 3mo after lovotibeglogene autotemcel infusion: combo may incr. risk of myelosuppression (additive effects)

• dolutegravir
Lyfgenia (lovotibeglogene autotemcel)

+

dolutegravir

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + dolutegravir

avoid combo; D/C dolutegravir at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• doravirine
Lyfgenia (lovotibeglogene autotemcel)

+

doravirine

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + doravirine

avoid combo; D/C doravirine at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• efavirenz
Lyfgenia (lovotibeglogene autotemcel)

+

efavirenz

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + efavirenz

avoid combo; D/C efavirenz at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• eflapegrastim (G-CSF)
Lyfgenia (lovotibeglogene autotemcel)

+

eflapegrastim (G-CSF)

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + eflapegrastim (G-CSF)

avoid combo x21 days after lovotibeglogene autotemcel infusion: combo may decr. lovotibeglogene autotemcel efficacy (mechanism unknown)

• elvitegravir
Lyfgenia (lovotibeglogene autotemcel)

+

elvitegravir

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + elvitegravir

avoid combo; D/C elvitegravir at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• emtricitabine
Lyfgenia (lovotibeglogene autotemcel)

+

emtricitabine

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + emtricitabine

avoid combo; D/C emtricitabine at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• enfuvirtide
Lyfgenia (lovotibeglogene autotemcel)

+

enfuvirtide

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + enfuvirtide

avoid combo; D/C enfuvirtide at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• etravirine
Lyfgenia (lovotibeglogene autotemcel)

+

etravirine

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + etravirine

avoid combo; D/C etravirine at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• fexinidazole
Lyfgenia (lovotibeglogene autotemcel)

+

fexinidazole

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + fexinidazole

use alternative or monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• filgrastim (G-CSF)
Lyfgenia (lovotibeglogene autotemcel)

+

filgrastim (G-CSF)

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + filgrastim (G-CSF)

avoid combo x21 days after lovotibeglogene autotemcel infusion: combo may decr. lovotibeglogene autotemcel efficacy (mechanism unknown)

• fostemsavir
Lyfgenia (lovotibeglogene autotemcel)

+

fostemsavir

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + fostemsavir

avoid combo; D/C fostemsavir at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• ganciclovir
Lyfgenia (lovotibeglogene autotemcel)

+

ganciclovir

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + ganciclovir

use alternative or monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• hydroxyurea
Lyfgenia (lovotibeglogene autotemcel)

+

hydroxyurea

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + hydroxyurea

avoid combo; D/C hydroxyurea at least 2mo prior to mobilization and until all apheresis cycles completed; D/C hydroxyurea at least 2 days prior to myeloablative conditioning: combo may interfere w/ gene transfer into apheresed cells; may incr. risk of myelosuppression, bleeding (antagonistic effects; additive effects)

• ibalizumab
Lyfgenia (lovotibeglogene autotemcel)

+

ibalizumab

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + ibalizumab

avoid combo; D/C ibalizumab at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• L-glutamine
Lyfgenia (lovotibeglogene autotemcel)

+

L-glutamine

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + L-glutamine

avoid combo; D/C L-glutamine at least 2mo prior to mobilization and until all apheresis cycles completed; D/C L-glutamine at least 2mo prior to myeloablative conditioning: combo may interfere w/ mobilization or conditioning agents (mechanism unknown)

• lamivudine
Lyfgenia (lovotibeglogene autotemcel)

+

lamivudine

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + lamivudine

avoid combo; D/C lamivudine at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• lopinavir/ritonavir
Lyfgenia (lovotibeglogene autotemcel)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + lopinavir/ ritonavir

avoid combo; D/C lopinavir/ritonavir at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• maraviroc
Lyfgenia (lovotibeglogene autotemcel)

+

maraviroc

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + maraviroc

avoid combo; D/C maraviroc at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• nevirapine
Lyfgenia (lovotibeglogene autotemcel)

+

nevirapine

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + nevirapine

avoid combo; D/C nevirapine at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• pegfilgrastim (G-CSF)
Lyfgenia (lovotibeglogene autotemcel)

+

pegfilgrastim (G-CSF)

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + pegfilgrastim (G-CSF)

avoid combo x21 days after lovotibeglogene autotemcel infusion: combo may decr. lovotibeglogene autotemcel efficacy (mechanism unknown)

• primaquine
Lyfgenia (lovotibeglogene autotemcel)

+

primaquine

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + primaquine

use alternative or monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• radium Ra 223 dichloride
Lyfgenia (lovotibeglogene autotemcel)

+

radium Ra 223 dichloride

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + radium Ra 223 dichloride

use alternative or monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• raltegravir
Lyfgenia (lovotibeglogene autotemcel)

+

raltegravir

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + raltegravir

avoid combo; D/C raltegravir at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• rilpivirine
Lyfgenia (lovotibeglogene autotemcel)

+

rilpivirine

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + rilpivirine

avoid combo; D/C rilpivirine at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• ritonavir
Lyfgenia (lovotibeglogene autotemcel)

+

ritonavir

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + ritonavir

avoid combo; D/C ritonavir at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• ropeginterferon alfa-2b
Lyfgenia (lovotibeglogene autotemcel)

+

ropeginterferon alfa-2b

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + ropeginterferon alfa-2b

use alternative or monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• sargramostim (GM-CSF)
Lyfgenia (lovotibeglogene autotemcel)

+

sargramostim (GM-CSF)

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + sargramostim (GM-CSF)

avoid combo x21 days after lovotibeglogene autotemcel infusion: combo may decr. lovotibeglogene autotemcel efficacy (mechanism unknown)

• tenofovir alafenamide
Lyfgenia (lovotibeglogene autotemcel)

+

tenofovir alafenamide

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + tenofovir alafenamide

avoid combo; D/C tenofovir alafenamide at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• tenofovir disoproxil
Lyfgenia (lovotibeglogene autotemcel)

+

tenofovir disoproxil

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + tenofovir disoproxil

avoid combo; D/C tenofovir disoproxil at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells (antagonistic effects)

• valganciclovir
Lyfgenia (lovotibeglogene autotemcel)

+

valganciclovir

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + valganciclovir

use alternative or monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• voxelotor
Lyfgenia (lovotibeglogene autotemcel)

+

voxelotor

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + voxelotor

avoid combo; D/C voxelotor at least 2mo prior to mobilization and until all apheresis cycles completed; D/C voxelotor at least 2mo prior to myeloablative conditioning: combo may interfere w/ mobilization or conditioning agents (mechanism unknown)

• zidovudine
Lyfgenia (lovotibeglogene autotemcel)

+

zidovudine

1 interaction

Avoid/Use Alternative

lovotibeglogene autotemcel + zidovudine

avoid combo; D/C zidovudine at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere w/ gene transfer into apheresed cells; may incr. risk of myelosuppression, bleeding (antagonistic effects; additive effects)

Monitor/Modify Tx

• abemaciclib
Lyfgenia (lovotibeglogene autotemcel)

+

abemaciclib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + abemaciclib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• acalabrutinib
Lyfgenia (lovotibeglogene autotemcel)

+

acalabrutinib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + acalabrutinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• ado-trastuzumab emtansine
Lyfgenia (lovotibeglogene autotemcel)

+

ado-trastuzumab emtansine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + ado-trastuzumab emtansine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• afamitresgene autoleucel
Lyfgenia (lovotibeglogene autotemcel)

+

afamitresgene autoleucel

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + afamitresgene autoleucel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• albendazole
Lyfgenia (lovotibeglogene autotemcel)

+

albendazole

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + albendazole

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• aldesleukin
Lyfgenia (lovotibeglogene autotemcel)

+

aldesleukin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + aldesleukin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• alemtuzumab
Lyfgenia (lovotibeglogene autotemcel)

+

alemtuzumab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + alemtuzumab

monitor CBC, bleeding s/sx; myelosuppression risk may be lower w/ alemtuzumab doses used for MS: combo may incr. risk of myelosuppression, bleeding (additive effects)

• allopurinol
Lyfgenia (lovotibeglogene autotemcel)

+

allopurinol

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + allopurinol

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• anti-thymocyte globulin
Lyfgenia (lovotibeglogene autotemcel)

+

anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + anti-thymocyte globulin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• arsenic trioxide
Lyfgenia (lovotibeglogene autotemcel)

+

arsenic trioxide

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + arsenic trioxide

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• asciminib
Lyfgenia (lovotibeglogene autotemcel)

+

asciminib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + asciminib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• asenapine
Lyfgenia (lovotibeglogene autotemcel)

+

asenapine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + asenapine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• atidarsagene autotemcel
Lyfgenia (lovotibeglogene autotemcel)

+

atidarsagene autotemcel

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + atidarsagene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• auranofin
Lyfgenia (lovotibeglogene autotemcel)

+

auranofin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + auranofin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• axicabtagene ciloleucel
Lyfgenia (lovotibeglogene autotemcel)

+

axicabtagene ciloleucel

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + axicabtagene ciloleucel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• azacitidine
Lyfgenia (lovotibeglogene autotemcel)

+

azacitidine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + azacitidine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• azathioprine
Lyfgenia (lovotibeglogene autotemcel)

+

azathioprine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + azathioprine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• balsalazide
Lyfgenia (lovotibeglogene autotemcel)

+

balsalazide

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + balsalazide

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• baricitinib
Lyfgenia (lovotibeglogene autotemcel)

+

baricitinib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + baricitinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• belantamab mafodotin
Lyfgenia (lovotibeglogene autotemcel)

+

belantamab mafodotin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + belantamab mafodotin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• belinostat
Lyfgenia (lovotibeglogene autotemcel)

+

belinostat

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + belinostat

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• bendamustine
Lyfgenia (lovotibeglogene autotemcel)

+

bendamustine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + bendamustine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• benznidazole
Lyfgenia (lovotibeglogene autotemcel)

+

benznidazole

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + benznidazole

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• betibeglogene autotemcel
Lyfgenia (lovotibeglogene autotemcel)

+

betibeglogene autotemcel

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + betibeglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• bevacizumab
Lyfgenia (lovotibeglogene autotemcel)

+

bevacizumab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + bevacizumab

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• bexarotene
Lyfgenia (lovotibeglogene autotemcel)

+

bexarotene

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + bexarotene

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• blinatumomab
Lyfgenia (lovotibeglogene autotemcel)

+

blinatumomab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + blinatumomab

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• bortezomib
Lyfgenia (lovotibeglogene autotemcel)

+

bortezomib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + bortezomib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• bosutinib
Lyfgenia (lovotibeglogene autotemcel)

+

bosutinib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + bosutinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• brentuximab vedotin
Lyfgenia (lovotibeglogene autotemcel)

+

brentuximab vedotin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + brentuximab vedotin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• brexucabtagene autoleucel
Lyfgenia (lovotibeglogene autotemcel)

+

brexucabtagene autoleucel

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + brexucabtagene autoleucel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• busulfan
Lyfgenia (lovotibeglogene autotemcel)

+

busulfan

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + busulfan

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• cabazitaxel
Lyfgenia (lovotibeglogene autotemcel)

+

cabazitaxel

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + cabazitaxel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• capecitabine
Lyfgenia (lovotibeglogene autotemcel)

+

capecitabine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + capecitabine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• carboplatin
Lyfgenia (lovotibeglogene autotemcel)

+

carboplatin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + carboplatin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• carfilzomib
Lyfgenia (lovotibeglogene autotemcel)

+

carfilzomib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + carfilzomib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• carmustine
Lyfgenia (lovotibeglogene autotemcel)

+

carmustine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + carmustine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• chlorambucil
Lyfgenia (lovotibeglogene autotemcel)

+

chlorambucil

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + chlorambucil

monitor CBC, bleeding s/sx; consider chlorambucil dose adjustment: combo may incr. risk of myelosuppression, bleeding (additive effects)

• cidofovir
Lyfgenia (lovotibeglogene autotemcel)

+

cidofovir

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + cidofovir

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• ciltacabtagene autoleucel
Lyfgenia (lovotibeglogene autotemcel)

+

ciltacabtagene autoleucel

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + ciltacabtagene autoleucel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• cisplatin
Lyfgenia (lovotibeglogene autotemcel)

+

cisplatin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + cisplatin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• cladribine injection
Lyfgenia (lovotibeglogene autotemcel)

+

cladribine injection

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + cladribine injection

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• clofarabine
Lyfgenia (lovotibeglogene autotemcel)

+

clofarabine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + clofarabine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• clozapine
Lyfgenia (lovotibeglogene autotemcel)

+

clozapine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + clozapine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• colchicine
Lyfgenia (lovotibeglogene autotemcel)

+

colchicine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + colchicine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• copanlisib
Lyfgenia (lovotibeglogene autotemcel)

+

copanlisib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + copanlisib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• crizotinib
Lyfgenia (lovotibeglogene autotemcel)

+

crizotinib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + crizotinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• cyclophosphamide
Lyfgenia (lovotibeglogene autotemcel)

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + cyclophosphamide

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• cytarabine
Lyfgenia (lovotibeglogene autotemcel)

+

cytarabine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + cytarabine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• dacarbazine
Lyfgenia (lovotibeglogene autotemcel)

+

dacarbazine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + dacarbazine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• dactinomycin
Lyfgenia (lovotibeglogene autotemcel)

+

dactinomycin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + dactinomycin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• dapsone
Lyfgenia (lovotibeglogene autotemcel)

+

dapsone

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + dapsone

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• daratumumab
Lyfgenia (lovotibeglogene autotemcel)

+

daratumumab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + daratumumab

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• dasatinib
Lyfgenia (lovotibeglogene autotemcel)

+

dasatinib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + dasatinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• daunorubicin
Lyfgenia (lovotibeglogene autotemcel)

+

daunorubicin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + daunorubicin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• decitabine
Lyfgenia (lovotibeglogene autotemcel)

+

decitabine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + decitabine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• deuruxolitinib
Lyfgenia (lovotibeglogene autotemcel)

+

deuruxolitinib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + deuruxolitinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• dexrazoxane
Lyfgenia (lovotibeglogene autotemcel)

+

dexrazoxane

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + dexrazoxane

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• dinutuximab
Lyfgenia (lovotibeglogene autotemcel)

+

dinutuximab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + dinutuximab

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• docetaxel
Lyfgenia (lovotibeglogene autotemcel)

+

docetaxel

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + docetaxel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• dostarlimab
Lyfgenia (lovotibeglogene autotemcel)

+

dostarlimab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + dostarlimab

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• doxorubicin
Lyfgenia (lovotibeglogene autotemcel)

+

doxorubicin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + doxorubicin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• duvelisib
Lyfgenia (lovotibeglogene autotemcel)

+

duvelisib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + duvelisib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• eflornithine
Lyfgenia (lovotibeglogene autotemcel)

+

eflornithine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + eflornithine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• elivaldogene autotemcel
Lyfgenia (lovotibeglogene autotemcel)

+

elivaldogene autotemcel

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + elivaldogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• elranatamab
Lyfgenia (lovotibeglogene autotemcel)

+

elranatamab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + elranatamab

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• enfortumab vedotin
Lyfgenia (lovotibeglogene autotemcel)

+

enfortumab vedotin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + enfortumab vedotin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• entrectinib
Lyfgenia (lovotibeglogene autotemcel)

+

entrectinib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + entrectinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• epcoritamab
Lyfgenia (lovotibeglogene autotemcel)

+

epcoritamab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + epcoritamab

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• epirubicin
Lyfgenia (lovotibeglogene autotemcel)

+

epirubicin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + epirubicin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• eribulin
Lyfgenia (lovotibeglogene autotemcel)

+

eribulin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + eribulin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• etoposide
Lyfgenia (lovotibeglogene autotemcel)

+

etoposide

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + etoposide

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• everolimus
Lyfgenia (lovotibeglogene autotemcel)

+

everolimus

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + everolimus

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• fam-trastuzumab deruxtecan
Lyfgenia (lovotibeglogene autotemcel)

+

fam-trastuzumab deruxtecan

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + fam-trastuzumab deruxtecan

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• fedratinib
Lyfgenia (lovotibeglogene autotemcel)

+

fedratinib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + fedratinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• floxuridine
Lyfgenia (lovotibeglogene autotemcel)

+

floxuridine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + floxuridine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• flucytosine
Lyfgenia (lovotibeglogene autotemcel)

+

flucytosine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + flucytosine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• fludarabine
Lyfgenia (lovotibeglogene autotemcel)

+

fludarabine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + fludarabine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• fluorouracil
Lyfgenia (lovotibeglogene autotemcel)

+

fluorouracil

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + fluorouracil

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• fluphenazine
Lyfgenia (lovotibeglogene autotemcel)

+

fluphenazine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + fluphenazine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• foscarnet
Lyfgenia (lovotibeglogene autotemcel)

+

foscarnet

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + foscarnet

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• fostamatinib
Lyfgenia (lovotibeglogene autotemcel)

+

fostamatinib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + fostamatinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• gemcitabine
Lyfgenia (lovotibeglogene autotemcel)

+

gemcitabine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + gemcitabine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• gemtuzumab ozogamicin
Lyfgenia (lovotibeglogene autotemcel)

+

gemtuzumab ozogamicin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + gemtuzumab ozogamicin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• givinostat
Lyfgenia (lovotibeglogene autotemcel)

+

givinostat

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + givinostat

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• glasdegib
Lyfgenia (lovotibeglogene autotemcel)

+

glasdegib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + glasdegib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• glofitamab
Lyfgenia (lovotibeglogene autotemcel)

+

glofitamab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + glofitamab

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• hydroxychloroquine
Lyfgenia (lovotibeglogene autotemcel)

+

hydroxychloroquine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + hydroxychloroquine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• ibritumomab tiuxetan
Lyfgenia (lovotibeglogene autotemcel)

+

ibritumomab tiuxetan

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + ibritumomab tiuxetan

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• ibrutinib
Lyfgenia (lovotibeglogene autotemcel)

+

ibrutinib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + ibrutinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• idarubicin
Lyfgenia (lovotibeglogene autotemcel)

+

idarubicin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + idarubicin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• idecabtagene vicleucel
Lyfgenia (lovotibeglogene autotemcel)

+

idecabtagene vicleucel

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + idecabtagene vicleucel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• idelalisib
Lyfgenia (lovotibeglogene autotemcel)

+

idelalisib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + idelalisib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• ifosfamide
Lyfgenia (lovotibeglogene autotemcel)

+

ifosfamide

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + ifosfamide

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• iloperidone
Lyfgenia (lovotibeglogene autotemcel)

+

iloperidone

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + iloperidone

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• imatinib
Lyfgenia (lovotibeglogene autotemcel)

+

imatinib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + imatinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• imetelstat
Lyfgenia (lovotibeglogene autotemcel)

+

imetelstat

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + imetelstat

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• inotuzumab ozogamicin
Lyfgenia (lovotibeglogene autotemcel)

+

inotuzumab ozogamicin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + inotuzumab ozogamicin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• interferon beta 1a
Lyfgenia (lovotibeglogene autotemcel)

+

interferon beta 1a

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + interferon beta 1a

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• interferon beta 1b
Lyfgenia (lovotibeglogene autotemcel)

+

interferon beta 1b

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + interferon beta 1b

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• interferon gamma 1b
Lyfgenia (lovotibeglogene autotemcel)

+

interferon gamma 1b

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + interferon gamma 1b

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• irinotecan
Lyfgenia (lovotibeglogene autotemcel)

+

irinotecan

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + irinotecan

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• isatuximab
Lyfgenia (lovotibeglogene autotemcel)

+

isatuximab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + isatuximab

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• ivosidenib
Lyfgenia (lovotibeglogene autotemcel)

+

ivosidenib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + ivosidenib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• ixabepilone
Lyfgenia (lovotibeglogene autotemcel)

+

ixabepilone

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + ixabepilone

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• leflunomide
Lyfgenia (lovotibeglogene autotemcel)

+

leflunomide

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + leflunomide

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• lenalidomide
Lyfgenia (lovotibeglogene autotemcel)

+

lenalidomide

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + lenalidomide

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• lifileucel
Lyfgenia (lovotibeglogene autotemcel)

+

lifileucel

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + lifileucel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• linezolid
Lyfgenia (lovotibeglogene autotemcel)

+

linezolid

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + linezolid

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• lisocabtagene maraleucel
Lyfgenia (lovotibeglogene autotemcel)

+

lisocabtagene maraleucel

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + lisocabtagene maraleucel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• lomustine
Lyfgenia (lovotibeglogene autotemcel)

+

lomustine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + lomustine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• lonafarnib
Lyfgenia (lovotibeglogene autotemcel)

+

lonafarnib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + lonafarnib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• loncastuximab tesirine
Lyfgenia (lovotibeglogene autotemcel)

+

loncastuximab tesirine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + loncastuximab tesirine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• lumateperone
Lyfgenia (lovotibeglogene autotemcel)

+

lumateperone

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + lumateperone

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• lurbinectedin
Lyfgenia (lovotibeglogene autotemcel)

+

lurbinectedin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + lurbinectedin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• lutetium Lu 177 dotatate
Lyfgenia (lovotibeglogene autotemcel)

+

lutetium Lu 177 dotatate

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + lutetium Lu 177 dotatate

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• lutetium Lu 177 vipivotide tetraxetan
Lyfgenia (lovotibeglogene autotemcel)

+

lutetium Lu 177 vipivotide tetraxetan

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + lutetium Lu 177 vipivotide tetraxetan

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• lymphocyte immune globulin, anti-thymocyte globulin
Lyfgenia (lovotibeglogene autotemcel)

+

lymphocyte immune globulin, anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + lymphocyte immune globulin, anti-thymocyte globulin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• melphalan
Lyfgenia (lovotibeglogene autotemcel)

+

melphalan

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + melphalan

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• mercaptopurine
Lyfgenia (lovotibeglogene autotemcel)

+

mercaptopurine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + mercaptopurine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• mesalamine
Lyfgenia (lovotibeglogene autotemcel)

+

mesalamine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + mesalamine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• mesalamine rectal
Lyfgenia (lovotibeglogene autotemcel)

+

mesalamine rectal

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + mesalamine rectal

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• methotrexate
Lyfgenia (lovotibeglogene autotemcel)

+

methotrexate

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + methotrexate

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• midostaurin
Lyfgenia (lovotibeglogene autotemcel)

+

midostaurin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + midostaurin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• mitomycin
Lyfgenia (lovotibeglogene autotemcel)

+

mitomycin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + mitomycin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• mitotane
Lyfgenia (lovotibeglogene autotemcel)

+

mitotane

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + mitotane

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• mitoxantrone
Lyfgenia (lovotibeglogene autotemcel)

+

mitoxantrone

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + mitoxantrone

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• mogamulizumab
Lyfgenia (lovotibeglogene autotemcel)

+

mogamulizumab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + mogamulizumab

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• momelotinib
Lyfgenia (lovotibeglogene autotemcel)

+

momelotinib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + momelotinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• mosunetuzumab
Lyfgenia (lovotibeglogene autotemcel)

+

mosunetuzumab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + mosunetuzumab

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• mycophenolate mofetil
Lyfgenia (lovotibeglogene autotemcel)

+

mycophenolate mofetil

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + mycophenolate mofetil

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• mycophenolic acid
Lyfgenia (lovotibeglogene autotemcel)

+

mycophenolic acid

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + mycophenolic acid

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• nelarabine
Lyfgenia (lovotibeglogene autotemcel)

+

nelarabine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + nelarabine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• nilotinib
Lyfgenia (lovotibeglogene autotemcel)

+

nilotinib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + nilotinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• niraparib
Lyfgenia (lovotibeglogene autotemcel)

+

niraparib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + niraparib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• obecabtagene autoleucel
Lyfgenia (lovotibeglogene autotemcel)

+

obecabtagene autoleucel

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + obecabtagene autoleucel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• obinutuzumab
Lyfgenia (lovotibeglogene autotemcel)

+

obinutuzumab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + obinutuzumab

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• ofatumumab
Lyfgenia (lovotibeglogene autotemcel)

+

ofatumumab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + ofatumumab

monitor CBC, bleeding s/sx; myelosuppression risk may be lower w/ ofatumumab doses used for MS: combo may incr. risk of myelosuppression, bleeding (additive effects)

• olaparib
Lyfgenia (lovotibeglogene autotemcel)

+

olaparib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + olaparib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• olsalazine
Lyfgenia (lovotibeglogene autotemcel)

+

olsalazine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + olsalazine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• omacetaxine mepesuccinate
Lyfgenia (lovotibeglogene autotemcel)

+

omacetaxine mepesuccinate

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + omacetaxine mepesuccinate

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• oxaliplatin
Lyfgenia (lovotibeglogene autotemcel)

+

oxaliplatin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + oxaliplatin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• paclitaxel
Lyfgenia (lovotibeglogene autotemcel)

+

paclitaxel

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + paclitaxel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• pacritinib
Lyfgenia (lovotibeglogene autotemcel)

+

pacritinib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + pacritinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• palbociclib
Lyfgenia (lovotibeglogene autotemcel)

+

palbociclib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + palbociclib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• panobinostat
Lyfgenia (lovotibeglogene autotemcel)

+

panobinostat

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + panobinostat

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• peginterferon alfa 2a
Lyfgenia (lovotibeglogene autotemcel)

+

peginterferon alfa 2a

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + peginterferon alfa 2a

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• peginterferon beta 1a
Lyfgenia (lovotibeglogene autotemcel)

+

peginterferon beta 1a

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + peginterferon beta 1a

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• pemetrexed
Lyfgenia (lovotibeglogene autotemcel)

+

pemetrexed

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + pemetrexed

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• penicillamine
Lyfgenia (lovotibeglogene autotemcel)

+

penicillamine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + penicillamine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• pentamidine
Lyfgenia (lovotibeglogene autotemcel)

+

pentamidine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + pentamidine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• pentostatin
Lyfgenia (lovotibeglogene autotemcel)

+

pentostatin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + pentostatin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• pirtobrutinib
Lyfgenia (lovotibeglogene autotemcel)

+

pirtobrutinib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + pirtobrutinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• polatuzumab vedotin
Lyfgenia (lovotibeglogene autotemcel)

+

polatuzumab vedotin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + polatuzumab vedotin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• pomalidomide
Lyfgenia (lovotibeglogene autotemcel)

+

pomalidomide

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + pomalidomide

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• ponatinib
Lyfgenia (lovotibeglogene autotemcel)

+

ponatinib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + ponatinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• pralatrexate
Lyfgenia (lovotibeglogene autotemcel)

+

pralatrexate

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + pralatrexate

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• procarbazine
Lyfgenia (lovotibeglogene autotemcel)

+

procarbazine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + procarbazine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• proguanil
Lyfgenia (lovotibeglogene autotemcel)

+

proguanil

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + proguanil

monitor CBC, bleeding s/sx, especially if concomitant renal impairment: combo may incr. risk of myelosuppression, bleeding (additive effects)

• pyrimethamine
Lyfgenia (lovotibeglogene autotemcel)

+

pyrimethamine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + pyrimethamine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• quizartinib
Lyfgenia (lovotibeglogene autotemcel)

+

quizartinib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + quizartinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• ribavirin
Lyfgenia (lovotibeglogene autotemcel)

+

ribavirin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + ribavirin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• ribociclib
Lyfgenia (lovotibeglogene autotemcel)

+

ribociclib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + ribociclib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• rifabutin
Lyfgenia (lovotibeglogene autotemcel)

+

rifabutin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + rifabutin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• rituximab
Lyfgenia (lovotibeglogene autotemcel)

+

rituximab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + rituximab

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• romidepsin
Lyfgenia (lovotibeglogene autotemcel)

+

romidepsin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + romidepsin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• rucaparib
Lyfgenia (lovotibeglogene autotemcel)

+

rucaparib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + rucaparib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• ruxolitinib
Lyfgenia (lovotibeglogene autotemcel)

+

ruxolitinib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + ruxolitinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• ruxolitinib topical
Lyfgenia (lovotibeglogene autotemcel)

+

ruxolitinib topical

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + ruxolitinib topical

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• sacituzumab govitecan
Lyfgenia (lovotibeglogene autotemcel)

+

sacituzumab govitecan

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + sacituzumab govitecan

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• sarilumab
Lyfgenia (lovotibeglogene autotemcel)

+

sarilumab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + sarilumab

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• satralizumab
Lyfgenia (lovotibeglogene autotemcel)

+

satralizumab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + satralizumab

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• selinexor
Lyfgenia (lovotibeglogene autotemcel)

+

selinexor

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + selinexor

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• sirolimus
Lyfgenia (lovotibeglogene autotemcel)

+

sirolimus

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + sirolimus

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• sirolimus albumin-bound
Lyfgenia (lovotibeglogene autotemcel)

+

sirolimus albumin-bound

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + sirolimus albumin-bound

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• stiripentol
Lyfgenia (lovotibeglogene autotemcel)

+

stiripentol

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + stiripentol

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• streptozocin
Lyfgenia (lovotibeglogene autotemcel)

+

streptozocin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + streptozocin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• succimer
Lyfgenia (lovotibeglogene autotemcel)

+

succimer

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + succimer

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• sulfasalazine
Lyfgenia (lovotibeglogene autotemcel)

+

sulfasalazine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + sulfasalazine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• tafasitamab
Lyfgenia (lovotibeglogene autotemcel)

+

tafasitamab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + tafasitamab

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• tagraxofusp
Lyfgenia (lovotibeglogene autotemcel)

+

tagraxofusp

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + tagraxofusp

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• talazoparib
Lyfgenia (lovotibeglogene autotemcel)

+

talazoparib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + talazoparib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• talquetamab
Lyfgenia (lovotibeglogene autotemcel)

+

talquetamab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + talquetamab

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• tarlatamab
Lyfgenia (lovotibeglogene autotemcel)

+

tarlatamab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + tarlatamab

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• tazemetostat
Lyfgenia (lovotibeglogene autotemcel)

+

tazemetostat

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + tazemetostat

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• teclistamab
Lyfgenia (lovotibeglogene autotemcel)

+

teclistamab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + teclistamab

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• temozolomide
Lyfgenia (lovotibeglogene autotemcel)

+

temozolomide

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + temozolomide

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• temsirolimus
Lyfgenia (lovotibeglogene autotemcel)

+

temsirolimus

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + temsirolimus

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• teplizumab
Lyfgenia (lovotibeglogene autotemcel)

+

teplizumab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + teplizumab

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• teriflunomide
Lyfgenia (lovotibeglogene autotemcel)

+

teriflunomide

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + teriflunomide

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• thalidomide
Lyfgenia (lovotibeglogene autotemcel)

+

thalidomide

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + thalidomide

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• thioguanine
Lyfgenia (lovotibeglogene autotemcel)

+

thioguanine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + thioguanine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• thiotepa
Lyfgenia (lovotibeglogene autotemcel)

+

thiotepa

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + thiotepa

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• tisagenlecleucel
Lyfgenia (lovotibeglogene autotemcel)

+

tisagenlecleucel

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + tisagenlecleucel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• tocilizumab
Lyfgenia (lovotibeglogene autotemcel)

+

tocilizumab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + tocilizumab

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• tofacitinib
Lyfgenia (lovotibeglogene autotemcel)

+

tofacitinib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + tofacitinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• topotecan
Lyfgenia (lovotibeglogene autotemcel)

+

topotecan

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + topotecan

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• trabectedin
Lyfgenia (lovotibeglogene autotemcel)

+

trabectedin

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + trabectedin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• trastuzumab
Lyfgenia (lovotibeglogene autotemcel)

+

trastuzumab

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + trastuzumab

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• treosulfan
Lyfgenia (lovotibeglogene autotemcel)

+

treosulfan

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + treosulfan

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• trifluridine
Lyfgenia (lovotibeglogene autotemcel)

+

trifluridine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + trifluridine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• trimethoprim
Lyfgenia (lovotibeglogene autotemcel)

+

trimethoprim

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + trimethoprim

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• upadacitinib
Lyfgenia (lovotibeglogene autotemcel)

+

upadacitinib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + upadacitinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• valproic acid
Lyfgenia (lovotibeglogene autotemcel)

+

valproic acid

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + valproic acid

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• venetoclax
Lyfgenia (lovotibeglogene autotemcel)

+

venetoclax

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + venetoclax

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• vinblastine
Lyfgenia (lovotibeglogene autotemcel)

+

vinblastine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + vinblastine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• vincristine
Lyfgenia (lovotibeglogene autotemcel)

+

vincristine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + vincristine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• vinorelbine
Lyfgenia (lovotibeglogene autotemcel)

+

vinorelbine

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + vinorelbine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• zanubrutinib
Lyfgenia (lovotibeglogene autotemcel)

+

zanubrutinib

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + zanubrutinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• ziv-aflibercept
Lyfgenia (lovotibeglogene autotemcel)

+

ziv-aflibercept

1 interaction

Monitor/Modify Tx

lovotibeglogene autotemcel + ziv-aflibercept

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)